Skip to main content

Table 6 Performance of PET/CT and cePET/CT in tumors, sites of disease, and clinical questions whose diagnostic results were significantly different between the two imaging modalities

From: Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography

 

PET/CT

cePET/CT

Tumor type

  

Head and neck cancer

  

Sensitivity (%)

71.33 (63.64–77.97)

82.67 (75.81–87.89)

Specificity (%)

46.30 (33.69–59.39)

48.15 (35.39–61.15)

Gastrointestinal cancer a

  

Sensitivity (%)

71.25 (60.54–80.01)

95.00 (87.84–98.04)

Specificity (%)

84.21 (62.43–94.48)

89.47 (68.61–97.06)

Site of disease

  

Abdomen

  

Sensitivity (%)

97.53 (91.44–99.32)

92.59 (84.77–96.56)

Specificity (%)

46.15 (23.21–70.86)

92.31 (66.69–98.63)

Questions

  

Restaging b

  

Sensitivity (%)

83.96 (75.81–89.74)

96.23 (90.70–98.52)

Specificity (%)

78.37 (52.33–92.50)

78.57 (52.41–92.43)

  1. Estimated parameters corresponding to each technique are presented with 95% confidence interval within parentheses.
  2. aIncluding esophageal, gastric, and colorectal cancer.
  3. bSuspected relapse or patients with potentially resectable metastatic disease.
  4. PET, positron emission tomography; CT, computed tomography; cePET/CT, contrast-enhanced PET/ CT.